POMALIDOMIDE: A NOVEL PROMISING IMMUNOMODULATORY AGENT IN THE TREATMENT OF REFRACTORY AND RELAPSED MULTIPLE MYELOMA
Journal Title: Journal of Drug Discovery and Therapeutics - Year 2013, Vol 1, Issue 3
Abstract
Revival of thalidomide in the treatment of multiple myeloma (MM) has paved a path to search for compounds with increased antiangiogenic and anti-tumor effects, but decreased side-effects resulting in the development of thalidomide analogues .After lenalidomide, recently pomalidomide (3 amino thalidomide) has come up as a potential immunomodulatory drug (IMiD) which is found to be effective in relapsing and refractory MM. This novel agent has recently been approved by USFDA on 8th February, 2013. Pomalidomide differs from existing immunomodulatory agents in being extremely potent and safe in comparison. Lack of cross resistance with the existing agents offers advantage for its use in MM not responding to thalidomide, lenalidomide and bortezomib. Manageable myelosuppression is the only demonstrable effect observed. This review elucidates the available evidence on efficacy and safety of this drug in refractory and relapsing MM after analyzing various studies of this drug. Searches of pubmed, Cochrane database, Medscape, Google and clinicaltrial.org were made for terms like pomalidomide, multiple myeloma, immunomodulatory drugs.
Authors and Affiliations
Ruchika Nandha*| Assistant Professor, Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Panjab University, Chandigarh , India, Kavita Sekhri| Assistant Professor, Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Panjab University, Chandigarh , India, Harpal Singh| Consultant, Department of Critical Care, Max Superspeciality hospital, Phase 6, Mohali, India
Keywords
Related Articles
- EP ID EP1361
- DOI -
- Views 496
- Downloads 29
FORMULATION AND EVALUATION OF SUSTAINED RELEASE TABLETS OF LABETALOL HYDROCHLORIDE USING HYDROPHILIC POLYMERS
Labetalol hydrochloride is used in treatment of hypertension. It has a short half life and undergoes extensive first pass metabolism. In the present study, labetalol hydrochloride 100 mg controlled release matrices were...
Possible Study of Drug-Drug Interactions between Lisinopril and Gliclazide in Experimental Animals
The most often problem in type II diabetic patients coexists with hypertension, the incidence of hypertension among diabetic patients is high. In this case, use a combination of medicine unavoidable (Polypharmacy). In su...
INDUSTRIAL PROCESS VALIDATION: A REVIEW
Validation is defined in the supplementary information section of the Federal Register as “a QA function that helps ensure drug product quality by providing documented evidence that the manufacturing process consistentl...
Gastrointestinal mucoadhesive drug delivery system: an overview
The current article has been focused on the mucoadhesive drug delivery system. Mucoadhesive drug delivery system shows promising future in enhancing the bioavailability and specific needs by utilizing the physiological c...
Recent advances in diagnostic and treatment of infectious disease leprosy
Being classified as a chronic disease than an acute infectious one, leprosy is associated with long lasting complications regarding immunology, disability and deformity. Throughout history, the leprotic person is always...